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those in women without PCOS (Homburg et al., 1992) , the Fifteen patients diagnosed with PCOS were recruited.
bioavailability of IGF-I may be raised by a decrease in Clinical diagnosis was based on chronic oligomenorrhoea IGFBP-1 plasma concentrations. A reduction in IGFBP-1 or amenorrhoea and hyperandrogenaemia. Clomiphene concentrations with respect to normal women has been demoncitrate was administered at a dose of 100 mg/day to all strated in women with PCOS (Suikkari et al., 1989) . These women from day 5 to day 9 of the spontaneous or medroxylower concentrations of IGFBP-1 seem to be a consequence progesterone acetate (MAP)-induced menstrual cycle.
of hyperinsulinaemia, a recognized feature of PCOS (Suikkari Blood sampling and a 2 h oral glucose loading test (75 g) et al., 1988) . It was recently demonstrated that PCOS is were performed the day before and after the course of clomiphene. Ovulation was confirmed in 13/15 PCOS associated with elevated serum concentrations of free IGF-I patients. Plasma concentrations of IGF-I decreased by measured with a new direct immunoradiometric assay (Van 31.5% (434 ⍨ 84 versus 297 ⍨ 71 ng/ml; P < 0.05) after Dessel et al., 1999) . 5 days of clomiphene therapy, whereas plasma concentra-
The aim of the present study was to evaluate the effect of tions of IGFBP-1 increased by~28.1% (26.3 ⍨ 4 versus clomiphene on plasma concentrations of IGF-I and IGFBP-1 36.6 ⍨ 7 ng/ml; P < 0.05). This gave a 56.5% reduction in and on insulin-resistance associated with PCOS. the IGF-I:IGFBP-1 ratio (21.9 versus 9.53). No significant changes in basal plasma concentrations of fasting insulin Materials and methods or area under the insulin curve were observed in response to oral loading. The present results show that clomiphene inducing ovulation in women with polycystic ovarian syndrome A baseline ultrasound scan was performed to evaluate the uterus whereas plasma concentrations of IGFBP-1 increased by and ovaries. Ovarian volumes were calculated from the maximum~2 8.1% (26.3 Ϯ 4.0 versus 36.6 Ϯ 7.0 ng/ml; P Ͻ 0.05). This longitudinal antero-posterior and transverse diameters. Ultrasonogave a 56.5% reduction in the IGF-I:IGFBP-1 ratio (21.9 graphic diagnosis of PCOS was based on the presence of 10 or more versus 9.53) ( Figure 1 ).
follicles (2-10 mm in diameter) in one or both ovaries.
The oral glucose loading curves of 7/15 subjects are shown in All women were normoprolactinaemic, normotensive and without insulin resistance associated with PCOS. Clomiphene treatment Intra-and inter-assay variations were 7.8 and 8.2% for LH, 6.2 was associated with a 28.1% increase in plasma concentrations and 6.5% for FSH, 3.2 and 3.4% for free testosterone, 3.9 and 3.8% of IGFBP-1 and with no changes in fasting insulin, fasting for IGF-I, 4.6 and 3.6% for IGFBP-1, 3.4 and 4.6% for testosterone, 4 and 4.8% for 17-OHP and 4.2 and 4.9% for oestradiol.
glucose, AUC insulin and glucose to insulin ratio. The absence of modifications in insulin concentrations after clomiphene insulin-resistant states such as short-term caloric restriction were calculated by the trapezoidal method. Basal hormone conand exercise do not improve insulin resistance (Mantzoros and centrations were compared using Student's two-tailed t-test for Moses, 1997) . paired data. Differences were considered significant for P Ͻ 0.05.
Although oral glucose tolerance test provides a convenient,
Relationships between variables were sought by Pearson productreadily available means of classifying individuals into normal, moment correlations (Glantz, 1988). mild to moderate and severe insulin resistant, euglycaemic clamp is considered the gold standard in the assessment of Results insulin action (Del Prato, 1999) . The fasting glucose:insulin ratio has been reported to Ovulation was confirmed in 13/15 PCOS patients by midluteal progesterone concentrations Ͼ35 nmol/l. Plasma concorrelate with dynamic testing of insulin in PCOS (Legro et al., 1998 ). In the current study patients were their own centrations of IGF-I decreased by 31.5% (434 Ϯ 84 versus 297 Ϯ 71 ng/ml; P Ͻ 0.05) after 5 days of clomiphene therapy, controls and the comparison was made between before and correlated with serum concentrations of insulin (Suikkari et al., 1989; Homburg et al., 1992) . This leads to an increased IGF-I:IGFBP-1 ratio and an increase in bioavailability of IGF-I. This hypothesis is confirmed by the recent demonstration of elevated serum free IGF-I in women with PCOS (Van Dessel et al., 1999) . Both high concentrations of insulin and IGF-I could amplify the effects of LH on granulosa cells, inducing terminal differentiation and leading to anovulation. The reduced IGF-I:IGFBP-1 ratio after clomiphene administration could therefore play a role in the induction of ovulation by this drug. IGFBP-1 is a hepatic product, the synthesis of which is inhibited by insulin (Suikkari et al., 1988). IGFBP-1 synthesis also takes place in ovarian granulosa before (grey) and after (black) clomiphene treatment in seven cells and endometrium (Koistinen et al., 1986) , and in both women (*: pmol/l/timeϫ1000).
sites IGFBP-1 synthesis is inhibited by insulin.
On the basis of the present results, the increase in IGFBP-1 cannot be explained by a reduction in insulin resistance, since after treatment. Using a highly sensitive measure of insulin no changes in the insulin curve were observed in response to sensitivity such as glucose:insulin ratio makes unlikely the oral glucose loading after clomiphene therapy. The increase in risk of missing real changes in insulin concentrations.
plasma concentrations of IGFBP-1 may therefore be a direct Several reports have focused on the changes of serum IGF-I effect of clomiphene. and IGFBP-1 during the ovulatory cycle (Jesionowska et al., Other hypotheses show that IGF-I directly suppresses secre-1990; Van Dessel et al., 1996) concluding that circulating tion of IGFBP-1 by granulosa cells (Dor et al., 1992) , decidua concentrations of IGF-I and IGFBP-1 are not menstrual cycle (Thraikill et al., 1990 ) and HEPG2 cells (Conover and Lee, dependent, hence observed modifications in these polypeptides 1990) and thus a primary reduction in IGF-I could itself be are direct effects of clomiphene administration and not the responsible for the increase in IGFBP-1. It is therefore possible result of having an ovulatory cycle.
that clomiphene causes an increase in IGFBP-1 by reducing The increase in IGFBP-1 could be responsible for the IGF-I. reduction in bioavailability of IGF-I in the ovary, as demonHowever, a direct effect of clomiphene cannot be excluded, strated by the great reduction in the IGF-I:IGFBP-1 ratio. since this drug, being an oestrogen receptor probe, may IGF-I may contribute to ovarian hyperandrogenaemia in PCOS theoretically act on all tissues that express receptors for by autocrine and paracrine mechanisms. IGF-I has been shown oestrogens. In fact, about 30 years ago, Schultz et al. (1968) to stimulate oestrogen production by granulosa cells (Erickson showed that [ 14 C]clomiphene accumulates in oestrogen target et al ., 1990) and to act synergistically with FSH and LH in tissues, such as the pituitary, hypothalamus, ovary, liver, uterus controlling granulosa cell aromatase concentrations (Garzo and and adrenal gland. Since the number of clomiphene non- Dorrington, 1984; Erickson et al., 1989) . It has also been responders is so small in the current study, it is not possible reported to act synergistically with LH to stimulate androgen to verify existing data on the predicitivity of the response to production (Cara and Rosenfield, 1988; Bergh et al., 1993) , clomiphene in terms of insulin resistance and IGFBP-1 (Tiitinen probably via its receptors on thecal cells (Bergh et al., 1993 (Bergh et al., ). et al., 1993 . In PCOS, plasma IGF-I concentrations are within the normal IGF-I has been shown to contribute to carbohydrate range whereas serum IGFBP-1 concentrations are reported to be significantly lower than in normal women and inversely economy. Availability of recombinant IGF-I has made possible Dor, J., Costritschi, N., Pariente, C. et al. (1992) Leo et al., 2000) . This drug has recently been proposed to Leo et al., 1999) . Hence the reduction in circulation. Fertil. Steril., 53, [88] [89] [90] [91] [92] [93] the IGF-I:IGFBP-1 ratio seems to be a fundamental element Katz, E., Ricciarelli, E. and Adashi, E.Y. (1993) The potential relevance of of initiation of ovulatory cycles in PCOS.
growth hormone to female reproductive physiology and pathophysiology.
In conclusion, the present results show that clomiphene does hyperandrogenic intrafollicular milieu recognized in PCOS. It
